The association of systemic lupus erythematosus (SLE) with thymoma occurs with significant frequency. 1 An autoimmune disorder of the blood, pure red cell aplasia (PRCA), may also be associated with thymoma 2 and SLE. 3 However, the occurrence of all three disorders, SLE, PRCA and thymoma, in the same patient is extremely rare. We are aware of one single case in which PRCA following thymectomy supervened in a patient with SLE. 4 Here we report the case of a patient who suffered from all three disorders, was thymectomised with a short-lived remission of PRCA and finally attained full remission of the same conditions following allogeneic haematopoietic SCT (allo-HSCT). However antinuclear antibodies (ANA) of the homogeneous subtype are still present at a significant titre over 1 year after transplant.
Our female patient, now aged 55 years, started suffering from polyarthralgia at the age of 45. ANA with the titre of 1:320 (type unspecified) were present, as well as a high ESR and reduced C3/C4. Further laboratory examinations showed strong positivity of ANA of the homogeneous subtype, anti-ds-DNA antibodies and lupus anticoagulant (LAC). A subsequent severe reticulocytopenic anaemia, with BM aspirates and biopsy sections consistent with PRCA, had a good response to antilymphocytic serum (ATG). However, she relapsed, and was subsequently treated with regular blood transfusions. Three years later a diagnosis of thymoma was made. Thymectomy was performed on 29 November 2010, and was followed by a favourable response of Hb (13 g/dL). The thymoma was of nodular epithelial nature. Because of the thymic residue, she was irradiated transcutaneously on the mediastinum with a linear accelerator. However, severe anaemia recurred, and she was referred to our Institution. The patient was conditioned with a combination of fludarabine (30 mg/m 2 × 4 days) and CY (30 mg/kg × 4 days), followed by TBI of 2 Gy. On 11 January 2013, she received a BM transplant from an HLA-identical sister, consisting of 3.1 × 10 8 /kg nucleated cells. Erythroblastic repopulation of the BM was ascertained on day +20. Because of incomplete donor chimerism on day +64, she received two gradually incremental DLI. In January 2014, her haematological data were good (Hb 127.0 g/L, RBC 4.0 × 10 12 /L, haematocrit 42.5, reticulocytes 1000 × 100 RBC, WBC 6.24 × 10 9 /L, plts 158 × 10 9 /L). Full donor chimerism is present in peripheral CD3 + lymphocytes (100% donor), whereas in the BM it is 78%. ANA are present at the titre of 1:320, and still belong to the homogeneous subtype. Anti ds-DNA antibodies are absent. This is, to our knowledge, the first case in the literature of a patient with the triad, SLE-thymoma-PRCA, having first undergone thymectomy, with attending irradiation and subsequently allo-HSCT, followed by resolution of PRCA. In addition, all clinical signs and symptoms of SLE have disappeared, but there is persistence, and a slight increment, of ANA of the homogeneous subtype over 1 year after transplantation. The syntropy thymoma--lupus is well known, 1 and, while thymectomy is mandatory in suspected malignancies, its effects on the coexisting SLE may be deleterious. 5 In contrast, the achievement of a long-term remission of PRCA following allo-HSCT is superimposable on the well-known results in SAA.
The effect of allo-HSCT on SLE is more complex. While autologous HSCT has become a widely used procedure in clinical practice, 6 with no evidence of an authentical cure, -and clinical evidence. Disappointingly, translation to the clinic has been less rewarding. No consistent pattern of a curative outcome in lupus patients has emerged, 7 and also in other autoimmune diseases there have been severe relapses despite full donor engraftment and chimerism. In some patients, mixed donor-recipient chimerism has been found to be both capable of controlling disease and also of heralding relapse. The persistence of key antibodies such as ANA in spite of allo-HSCT is a typical example of clinical silencing but persisting immunological activity. The existence of long-lived plasmacytes in specialised survival niches has been considered to be an important contributor to the persistence of autoimmunity. 9 The significance of autoantibodies as biomarkers, predictors of SLE as well as of autoimmune diseases in general, raises questions concerning the achievement of an authentic cure by means of HSCT, even of the allogeneic type. Although clinical improvement has been substantial in our patient, the persistence of ANA makes the achievement of an authentic cure still apparently 'elusive'. 
